The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

Scientists say they have achieved a "first" in the development of drugs to treat Alzheimer's disease. In a study published in the journal Alzheimer's & Dementia, a team of researchers report the ...

An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer's Disease. For the first time, scientists have developed a drug that works on ...

An international team of researchers led by Lancaster University has made a promising breakthrough in the development of ...

Researchers believe their work will have a significant impact on drug discovery efforts in the field of neurodegenerative ...

Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in ...

The research, published in Alzheimer's & Dementia ... we have a drug which is effective in inhibiting both these regions. This dual-targeting mechanism is significant because it addresses both ...

Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 ...

Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk ...

AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models.

Tau proteins help to stabilise the internal skeleton of nerve cells (neurons) in the brain. But in Alzheimer’s disease, these ...